Melatonin and IL-25 modulate apoptosis and angiogenesis mediators in metastatic (CF-41) and non-metastatic (CMT-U229) canine mammary tumour cells

2017 ◽  
Vol 15 (4) ◽  
pp. 1572-1584 ◽  
Author(s):  
G. B. Gelaleti ◽  
T. F. Borin ◽  
L. B. Maschio-Signorini ◽  
M. G. Moschetta ◽  
E. Hellmén ◽  
...  
2002 ◽  
Vol 85 (3) ◽  
pp. 470-481 ◽  
Author(s):  
Ugo Pagnini ◽  
Salvatore Florio ◽  
Luca Crispino ◽  
Giuseppe Pagnini ◽  
Donato Colangelo ◽  
...  

2019 ◽  
Vol 46 (3) ◽  
pp. 369-374
Author(s):  
Martina Argano ◽  
Raffaella De Maria ◽  
Claus Vogl ◽  
Katrin Rodlsberger ◽  
Paolo Buracco ◽  
...  

2019 ◽  
Vol 124 ◽  
pp. 240-247
Author(s):  
Jing Dong ◽  
Wenhui Yang ◽  
Jiaqi Han ◽  
Rongjie Cheng ◽  
Xin Guo ◽  
...  

2000 ◽  
Vol 69 (3) ◽  
pp. 255-262 ◽  
Author(s):  
U. PAGNINI ◽  
S. FLORIO ◽  
P. LOMBARDI ◽  
D. D’ANGELO ◽  
L. AVALLONE ◽  
...  

2004 ◽  
Vol 502 (3) ◽  
pp. 185-193 ◽  
Author(s):  
Daniël Duijsings ◽  
Martin Houweling ◽  
Arie B. Vaandrager ◽  
Jan A. Mol ◽  
Katja J. Teerds

2021 ◽  
Vol 17 (1) ◽  
Author(s):  
Michela Levi ◽  
Roberta Salaroli ◽  
Federico Parenti ◽  
Raffaella De Maria ◽  
Augusta Zannoni ◽  
...  

Abstract Background Doxorubicin (DOX) is widely used in both human and veterinary oncology although the onset of multidrug resistance (MDR) in neoplastic cells often leads to chemotherapy failure. Better understanding of the cellular mechanisms that circumvent chemotherapy efficacy is paramount. The aim of this study was to investigate the response of two canine mammary tumour cell lines, CIPp from a primary tumour and CIPm, from its lymph node metastasis, to exposure to EC50(20h) DOX at 12, 24 and 48 h of treatment. We assessed the uptake and subcellular distribution of DOX, the expression and function of P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP), two important MDR mediators. To better understand this phenomenon the effects of DOX on the cell cycle and Ki67 cell proliferation index and the expression of p53 and telomerase reverse transcriptase (TERT) were also evaluated by immunocytochemistry (ICC). Results Both cell lines were able to uptake DOX within the nucleus at 3 h treatment while at 48 h DOX was absent from the intracellular compartment (assessed by fluorescence microscope) in all the surviving cells. CIPm, originated from the metastatic tumour, were more efficient in extruding P-gp substrates. By ICC and qRT-PCR an overall increase in both P-gp and BCRP were observed at 48 h of EC50(20h) DOX treatment in both cell lines and were associated with a striking increase in the percentage of p53 and TERT expressing cells by ICC. The cell proliferation fraction was decreased at 48 h in both cell lines and cell cycle analysis showed a DOX-induced arrest in the S phase for CIPp, while CIPm had an increase in cellular death without arrest. Both cells lines were therefore composed by a fraction of cells sensible to DOX that underwent apoptosis/necrosis. Conclusions DOX administration results in interlinked modifications in the cellular population including a substantial effect on the cell cycle, in particular arrest in the S phase for CIPp and the selection of a subpopulation of neoplastic cells bearing MDR phenotype characterized by P-gp and BCRP expression, TERT activation, p53 accumulation and decrease in the proliferating fraction. Important information is given for understanding the dynamic and mechanisms of the onset of drug resistance in a neoplastic cell population.


1990 ◽  
Vol 269 (3) ◽  
pp. 633-637 ◽  
Author(s):  
M E Monaco ◽  
M Attinasi ◽  
K Koréh

Both vasopressin and bradykinin activate the phosphoinositide cycle in WRK-1 rat mammary tumour cells. When the two agonists are added simultaneously, partial additivity is observed with respect to disappearance of prelabelled phosphoinositides and accumulation of inositol phosphates; no additivity is observed with respect to resynthesis of phosphatidylinositol as assessed by monitoring [32P]Pi incorporation. Lack of complete additivity can be explained, at least in part, by heterologous desensitization. In order to determine whether the two agonists were accessing a common or individual hormone-sensitive phosphoinositide pools, cells were incubated with [32P]Pi in the presence of either vasopressin or bradykinin and subsequently restimulated with the alternative agonist. The lipid pool labelled in the presence of either agonist was sensitive to subsequent treatment by the other ligand, suggesting a common phosphoinositide pool. However, when cells were incubated with [32P]Pi in the absence of agonists, the time course of labelling of the hormone-sensitive pool was different for bradykinin and vasopressin, with that for bradykinin becoming labelled within a much shorter time. Thus although there is a significant overlap between the phosphoinositide pools responding to vasopressin and bradykinin, there is a small fraction of the hormone-sensitive lipid which responds only to bradykinin.


2009 ◽  
Vol 64 (1-2) ◽  
pp. 32-36 ◽  
Author(s):  
Camila B. de A. Carli ◽  
Djamile C. de Matos ◽  
Flávia C. M. Lopes ◽  
Danielle C. G. Maia ◽  
Maristela B. Dias ◽  
...  

1The purpose of the present study was to investigate antitumour and anti-inflammatory activities of flavonoids isolated from Byrsonima crassa, Davilla elliptica and Mouriri pusa. The antitumour activity was measured by the MTT assay in murine mammary tumour cells (LM2) and the IC50 values of the fl avonoids tested ranged from (31.5 ± 2.97) to (203.1 ± 5.9) μg/ml. The fl avonoids (myricetin-3-O-α-L-rhamnopyranoside) and 3 (quercetin-3-Ogalactopyranoside) from D. elliptica were the most active ones against the tumour cells. The same samples were tested to determine the inhibition of the release of nitric oxide (NO) and of the tumour necrosis factor-alpha (TNF-α) in murine macrophages by the Griess and ELISA sandwich assay, respectively. Almost all the samples showed inhibitory activity to the release of NO but not of TNF-α. Of all substances tested, flavonoids 2 (quercetin) and 6 (myricetin) may show promising activity in the treatment of murine breast cancer by immunomodulatory and antiproliferative activities.


Sign in / Sign up

Export Citation Format

Share Document